Target intelligence / Profile preview

Peptidoglycan D-alanyl-D-alanine terminus of lipid II precursors (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall precursor, Peptidoglycan component, Other
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus of lipid II precursors is a critical structural motif in the biosynthesis of the bacterial cell wall, specifically in Gram-positive bacteria [1]. Lipid II is the final membrane-associated intermediate that carries the peptidoglycan building blocks across the cytoplasmic membrane [2]. The D-Ala-D-Ala dipeptide at the end of the pentapeptide chain serves as the substrate for transpeptidase enzymes (penicillin-binding proteins) which catalyze the cross-linking of peptidoglycan layers, providing mechanical strength to the cell wall [3]. This terminus is the primary molecular target for glycopeptide antibiotics, such as vancomycin [1]. By binding with high affinity to the D-Ala-D-Ala motif via hydrogen bonding, these drugs sterically inhibit the enzymatic incorporation of the precursor into the growing peptidoglycan polymer, leading to cell wall weakening and osmotic lysis [4]. Resistance often arises through the modification of this target to D-alanyl-D-lactate (D-Ala-D-Lac), which significantly reduces antibiotic binding affinity [5]. Sources: [1] StatPearls (https://www.ncbi.nlm.nih.gov/books/NBK459363/); [2] Nature Reviews Microbiology (https://www.nature.com/articles/nrmicro2020); [3] UniProt (https://www.uniprot.org/locations/SL-0219); [4] JBC (https://www.jbc.org/article/S0021-9258(20)31840-7/fulltext); [5] CDC (https://www.cdc.gov/hai/organisms/vre/vre.html); [6] Mayo Clinic (https://www.mayoclinic.org/drugs-supplements/vancomycin-intravenous-route/side-effects/drg-20068893).

Other names
D-Ala-D-Ala terminusLipid II pentapeptide terminusD-alanyl-D-alanine dipeptidePeptidoglycan precursor C-terminus
02

Mechanism of action

Binding to the D-Ala-D-Ala terminus of Lipid II, sterically hindering the transglycosylation and transpeptidation steps of peptidoglycan synthesis [1, 4].

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingOther
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndromeDevelopment of antibiotic resistance
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

VanA geneVanB geneMinimum Inhibitory Concentration (MIC)

Beyond the preview

Go deeper on Peptidoglycan D-alanyl-D-alanine terminus of lipid II precursors (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan D-alanyl-D-alanine terminus of lipid II precursors (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call